Literature DB >> 11106577

Immunohistochemical analysis of endothelial-monocyte-activating polypeptide-II expression in vivo.

J C Murray1, G Barnett, M Tas, A Jakobsen, J Brown, D Powe, C Clelland.   

Abstract

Endothelial-monocyte activating polypeptide (EMAP)-II is a novel molecule with cytokine-like pro-inflammatory properties, inducing procoagulant activity on the surface of endothelial cells and monocyte/macrophages in vitro, as well as up-regulating E- and P-selectin expression. EMAP-II is chemotactic for monocytes/macrophages and neutrophils, and stimulates myeloperoxidase release from neutrophils. Injection of EMAP-II into the mouse footpad induces an acute inflammatory response, although some regression occurs in response to direct injection of EMAP-II into murine tumors. Very little is known about the expression of EMAP-II in normal tissues of mice or humans, or about its function in vivo. We developed polyclonal antibodies against EMAP-II using recombinant protein produced in Escherichia coli, and used these antibodies to carry out an immunohistochemical study of the occurrence and distribution of EMAP-II in human tissues. The distribution of EMAP-II protein is relatively restricted, occurring primarily in endocrine organs, in cells of neuroendocrine origin, but also in tissues with high turnover. EMAP-II is strongly expressed in secretory epithelial cells of the thyroid, pancreas, adrenal and salivary glands, among others, as well as in neurons and subsets of monocytes/macrophages. It is also found in the epithelium of the small and large intestines. We conclude that EMAP-II expression is usually, but not always, associated with tissues that display high turnover and high levels of protein synthesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106577      PMCID: PMC1885784          DOI: 10.1016/S0002-9440(10)64843-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  18 in total

1.  Identification and partial purification of a novel tumor-derived protein that induces tissue factor on cultured human endothelial cells.

Authors:  M Noguchi; T Sakai; W Kisiel
Journal:  Biochem Biophys Res Commun       Date:  1989-04-14       Impact factor: 3.575

2.  The use of catalyzed reporter deposition as a means of signal amplification in a variety of formats.

Authors:  M N Bobrow; G J Litt; K J Shaughnessy; P C Mayer; J Conlon
Journal:  J Immunol Methods       Date:  1992-06-24       Impact factor: 2.303

3.  Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress.

Authors:  G Barnett; A M Jakobsen; M Tas; K Rice; J Carmichael; J C Murray
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

4.  Measurement of tissue factor messenger RNA levels in human endothelial cells by a quantitative RT-PCR assay.

Authors:  A J Pötgens; N H Lubsen; G van Altena; J G Schoenmakers; D J Ruiter; R M de Waal
Journal:  Thromb Haemost       Date:  1994-02       Impact factor: 5.249

5.  Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms.

Authors:  J Kao; J Ryan; G Brett; J Chen; H Shen; Y G Fan; G Godman; P C Familletti; F Wang; Y C Pan
Journal:  J Biol Chem       Date:  1992-10-05       Impact factor: 5.157

6.  Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II.

Authors:  J Kao; K Houck; Y Fan; I Haehnel; S K Libutti; M L Kayton; T Grikscheit; J Chabot; R Nowygrod; S Greenberg
Journal:  J Biol Chem       Date:  1994-10-07       Impact factor: 5.157

7.  Selective induction of endothelial cell tissue factor in the presence of a tumour-derived mediator: a potential mechanism of flavone acetic acid action in tumour vasculature.

Authors:  J C Murray; M Clauss; J Denekamp; D Stern
Journal:  Int J Cancer       Date:  1991-09-09       Impact factor: 7.396

8.  A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin.

Authors:  M Clauss; J C Murray; M Vianna; R de Waal; G Thurston; P Nawroth; H Gerlach; R Bach; P C Familletti; D Stern
Journal:  J Biol Chem       Date:  1990-04-25       Impact factor: 5.157

9.  Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells.

Authors:  M A Schwarz; J Kandel; J Brett; J Li; J Hayward; R E Schwarz; O Chappey; J L Wautier; J Chabot; P Lo Gerfo; D Stern
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

10.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.

Authors:  M Clauss; M Gerlach; H Gerlach; J Brett; F Wang; P C Familletti; Y C Pan; J V Olander; D T Connolly; D Stern
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  4 in total

1.  EMAP-II-dependent lymphocyte killing is associated with hypoxia in colorectal cancer.

Authors:  M M S Youssef; P Symonds; I O Ellis; J C Murray
Journal:  Br J Cancer       Date:  2006-08-22       Impact factor: 7.640

2.  Changes in the expression of endothelial monocyte‑activating polypeptide II in the rat hippocampus following status epilepticus.

Authors:  Chun Li; Weining Ma; Yajuan Zhao; Hua Wang
Journal:  Int J Mol Med       Date:  2020-12-03       Impact factor: 4.101

3.  EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma.

Authors:  Manal Mohamed Saber
Journal:  J Immunol Res       Date:  2022-09-12       Impact factor: 4.493

4.  Modulation of neutrophil function by the tripeptide feG.

Authors:  Ronald D Mathison; A Dean Befus; Joseph S Davison; Richard C Woodman
Journal:  BMC Immunol       Date:  2003-03-04       Impact factor: 3.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.